Literature DB >> 22161689

Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.

Raphael Rutkowski1, Inga Mertens-Walker, Jessica E Lisle, Adrian C Herington, Sally-Anne Stephenson.   

Abstract

Overexpression of the receptor tyrosine kinase EphB4 is common in epithelial cancers and linked to tumor progression by promoting angiogenesis, increasing survival and facilitating invasion and migration. However, other studies have reported loss of EphB4 suggesting a tumor suppressor function in some cancers. These opposing roles may be regulated by (i) the presence of the primary ligand ephrin-B2 that regulates pathways involved in tumor suppression or (ii) the absence of ephrin-B2 that allows EphB4 signaling via ligand-independent pathways that contribute to tumor promotion. To explore this theory, EphB4 was overexpressed in the prostate cancer cell line 22Rv1 and the mammary epithelial cell line MCF-10A. Overexpressed EphB4 localized to lipid-rich regions of the plasma membrane and confirmed to be ligand-responsive as demonstrated by increased phosphorylation of ERK1/2 and internalization. EphB4 overexpressing cells demonstrated enhanced anchorage-independent growth, migration and invasion, all characteristics associated with an aggressive phenotype, and therefore supporting the hypothesis that overexpressed EphB4 facilitates tumor promotion. Importantly, these effects were reversed in the presence of ephrin-B2 which led to a reduction in EphB4 protein levels, demonstrating that ligand-dependent signaling is tumor suppressive. Furthermore, extended ligand stimulation caused a significant decrease in proliferation that correlated with a rise in caspase-3/7 and -8 activities. Together, these results demonstrate that overexpression of EphB4 confers a transformed phenotype in the case of MCF-10A cells and an increased metastatic phenotype in the case of 22Rv1 cancer cells and that both phenotypes can be restrained by stimulation with ephrin-B2, in part by reducing EphB4 levels.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22161689     DOI: 10.1002/ijc.27392

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  31 in total

1.  Analysis of differentially expressed genes, clinical value and biological pathways in prostate cancer.

Authors:  Zhaohui He; Fucai Tang; Zechao Lu; Yucong Huang; Hanqi Lei; Zhibiao Li; Guohua Zeng
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

Review 2.  EphB4: A promising target for upper aerodigestive malignancies.

Authors:  Ravi Salgia; Prakash Kulkarni; Prakash S Gill
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-01-31       Impact factor: 10.680

Review 3.  [Research progress on the expression and function of erythropoietin-producing hepatomocellular receptors and their receptor-interacting proteins in oral-related diseases].

Authors:  Qi Wang; Yan Liu; Yun Zhao; Li-Zhong Sun; Lin-Xuan Wang; Mei Han; Fang-Lin Mi
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-04-01

Review 4.  Cell mates: paracrine and stromal targets for prostate cancer therapy.

Authors:  Pavel Sluka; Ian D Davis
Journal:  Nat Rev Urol       Date:  2013-07-16       Impact factor: 14.432

Review 5.  Membrane-mediated regulation of vascular identity.

Authors:  Takuya Hashimoto; Masayuki Tsuneki; Trenton R Foster; Jeans M Santana; Hualong Bai; Mo Wang; Haidi Hu; Jesse J Hanisch; Alan Dardik
Journal:  Birth Defects Res C Embryo Today       Date:  2016-03-17

6.  Diagnostic and prognostic value of tissue and circulating levels of Ephrin-A2 in prostate cancer.

Authors:  Shibao Li; Zhiyuan Wu; Yuming Chen; Zhihua Kang; Hua Wang; Ping He; Xinju Zhang; Tingting Hu; Qunfeng Zhang; Yanqun Cai; Xiao Xu; Ming Guan
Journal:  Tumour Biol       Date:  2015-11-11

7.  Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.

Authors:  Diana L Hanna; Fotios Loupakis; Dongyun Yang; Chiara Cremolini; Marta Schirripa; Meng Li; Satoshi Matsusaka; Martin D Berger; Yuji Miyamoto; Wu Zhang; Yan Ning; Carlotta Antoniotti; Lisa Salvatore; Miriana Moran; Gary Zeger; Stephanie H Astrow; Alfredo Falcone; Heinz-Josef Lenz
Journal:  Clin Colorectal Cancer       Date:  2018-03-14       Impact factor: 4.481

8.  Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.

Authors:  Irene Guijarro-Muñoz; Antonio Sánchez; Esther Martínez-Martínez; Jose M García; Clara Salas; Mariano Provencio; Luis Alvarez-Vallina; Laura Sanz
Journal:  Med Oncol       Date:  2013-04-12       Impact factor: 3.064

Review 9.  The critical role of the interplays of EphrinB2/EphB4 and VEGF in the induction of angiogenesis.

Authors:  Enming Du; Xue Li; Siyu He; Xiaohua Li; Shikun He
Journal:  Mol Biol Rep       Date:  2020-06-02       Impact factor: 2.316

10.  Low Expression of EphB2, EphB3, and EphB4 in Bladder Cancer: Novel Potential Indicators of Muscular Invasion.

Authors:  Tae Ho Lee; Jin Hyung Heo; Ju Yeon Jeong; Gee Hoon Lee; Dong Soo Park; Tae Hoen Kim
Journal:  Yonsei Med J       Date:  2021-08       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.